Skip to main content

Table 1 Demographics and clinical characteristics of RCC patients treated with sunitinib with a 3-month follow-up.

From: Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

  1. ASA Acetylsalicylic acid (aspirin), ATOR Atorvastatin, GI Gastrointestinal, NA Not available, RCC Renal cell carcinoma, † Patient deceased during follow-up period, ↓ Dosage Decreased dosage of sunitinib due to side effects.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us